Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
NCT05559164
This study is recruiting at 9 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cardiac Toxicity
- Early-stage Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Rutgers, The State University of New Jersey
- Last updated on ClinicalTrials.gov
- November 14, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 9
- Trinitas Hospital and Comprehensive Cancer Center · Elizabeth, NJ
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton · Hamilton, NJ
- RWJBarnabas Health - - Jersey City Medical Medical · Jersey City, NJ
- Monmouth Medical Center Southern Campus · Lakewood, NJ
- Monmouth Community Medical · Long Branch, NJ
- RWJBarnabas Health - Monmouth Medical Center · Long Branch, NJ
- Rutgers Cancer Institute of New Jersey · New Brunswick, NJ
- RWJBarnabas Health - Newark Beth Israel Medical Center · Newark, NJ
- RWJBarnabas Health - Robert Wood Johnson University Hospital · Somerset, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.